Johnson & Johnson (JNJ)vsRani Therapeutics Holdings Inc (RANI)
JNJ
Johnson & Johnson
$232.77
-2.16%
HEALTHCARE · Cap: $536.54B
RANI
Rani Therapeutics Holdings Inc
$0.88
+2.03%
HEALTHCARE · Cap: $107.58M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 3040670% more annual revenue ($96.36B vs $3.17M). JNJ leads profitability with a 21.8% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
RANI
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-71.4%
Fair Value
$135.80
Current Price
$232.77
$96.97 premium
Margin of Safety
+77.3%
Fair Value
$5.50
Current Price
$0.88
$4.62 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Revenue surging 893.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : RANI
The strongest argument for RANI centers on Revenue Growth, Debt/Equity. Revenue growth of 893.0% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : RANI
The primary concerns for RANI are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
JNJ profiles as a mature stock while RANI is a hypergrowth play — different risk/reward profiles.
RANI carries more volatility with a beta of 0.76 — expect wider price swings.
RANI is growing revenue faster at 893.0% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 28/100), backed by strong 21.8% margins. RANI offers better value entry with a 77.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Rani Therapeutics Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rani Therapeutics Holdings Inc. is at the forefront of biotechnology innovation, transforming injectable therapies with its proprietary RaniPill™ technology that allows for oral delivery of biologics. This cutting-edge platform addresses significant patient adherence challenges, aiming to enhance treatment efficacy while meeting the rising demand for non-invasive therapeutic options. With a robust and diverse pipeline targeting multiple therapeutic areas, Rani Therapeutics is strategically positioned to disrupt traditional drug delivery paradigms. The company's commitment to research and development, coupled with strategic collaborations, underpins its potential for significant growth and impactful contributions to the pharmaceutical landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?